Cargando…

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown. Therefore, tofacitinib effects on synovial pathobiology were investigated. METHODS: A randomised...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyle, D L, Soma, K, Hodge, J, Kavanaugh, A, Mandel, D, Mease, P, Shurmur, R, Singhal, A K, Wei, N, Rosengren, S, Kaplan, I, Krishnaswami, S, Luo, Z, Bradley, J, Firestein, G S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Basic and Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431345/ https://www.ncbi.nlm.nih.gov/pubmed/25398374 http://dx.doi.org/10.1136/annrheumdis-2014-206028

Ejemplares similares

Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors
por: Gao, W, et al.
Publicado: (2016)

Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway
por: González-Alvaro, I, et al.
Publicado: (2008)

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism
por: Adorni, Maria Pia, et al.
Publicado: (2023)

Joint Location–Specific JAK‐STAT Signaling in Rheumatoid Arthritis Fibroblast‐like Synoviocytes
por: Hammaker, Deepa, et al.
Publicado: (2019)

EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo
por: Jensen, Katharine V, et al.
Publicado: (2020)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
por: Di Benedetto, Paola, et al.
Publicado: (2021)

Epileptic Neurons Know JAK/STAT3
por: Kumari, Shikha, et al.
Publicado: (2023)

Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice
por: Casado-García, Ana, et al.
Publicado: (2022)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

Quantitative biomarker analysis of synovial gene expression by real-time PCR
por: Boyle, David L, et al.
Publicado: (2003)

Runx1 promotes the development of glioma cells by regulating JAK-STAT signalling pathway
por: Zhang, Yong, et al.
Publicado: (2019)

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study
por: Buch, M H, et al.
Publicado: (2009)

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
por: Kaine, Jeffrey, et al.
Publicado: (2020)

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
por: Palmroth, Maaria, et al.
Publicado: (2021)

Tofacitinib Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Blocking the JAK-STAT1/STAT3 Signaling Pathway
por: Yun, Yang, et al.
Publicado: (2021)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis
por: Yeo, L, et al.
Publicado: (2016)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide
por: Wythe, Sarah E, et al.
Publicado: (2013)

A JAK/STAT invasion
por: Wells, William A.
Publicado: (2002)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

The Drosophila JAK-STAT pathway
por: Zeidler, Martin P, et al.
Publicado: (2013)

Evolution of the JAK-STAT pathway
por: Liongue, Clifford, et al.
Publicado: (2013)

The JAK-STAT pathway at 20
por: Darnell, Jr., James E.
Publicado: (2012)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

JAK/STAT pathway in pathology of rheumatoid arthritis (Review)
por: Ciobanu, Dana Alexandra, et al.
Publicado: (2020)

The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice
por: Wang, Han, et al.
Publicado: (2019)

Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis
por: Reynolds, G, et al.
Publicado: (2016)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
por: Morelli, Martina, et al.
Publicado: (2018)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

The prolactin receptor is expressed in rheumatoid arthritis and psoriatic arthritis synovial tissue and contributes to macrophage activation
por: Tang, Man Wai, et al.
Publicado: (2016)

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
por: Govaerts, Inge, et al.
Publicado: (2019)

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy
por: Koppikar, Priya, et al.
Publicado: (2012)

JAK/STAT signaling and human in vitro myogenesis
por: Trenerry, Marissa K, et al.
Publicado: (2011)

Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting
por: Zanders, Lukas, et al.
Publicado: (2021)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

JAK-STAT in heterochromatin and genome stability
por: Silver-Morse, Louise, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lp8pcg7noedvko5l5c151champ